A new study suggests that administering boys with cervical cancer vaccine shots Gardasil to prevent the virus from passing to girls through sex may not be worth the price of doing so on a widespread basis.

Merck & Co., the maker of Gardasil, has requested the Food and Drug Administration (FDA) to approve the vaccine for use in boys and men between the ages of 9-26 to waive off genital warts caused by common strains of human pappilomavirus (HPV), which are also the cause of cervical cancer in females.

FDA is continuing to review whether it should expand the use to boys and men, according to a news report by reuters.

The drug has been approved already, for women and girls as young as 11 to prevent cervical cancer.

It was found in a recent study that Gardasil has caused at least 47 deaths and thousands of reports of adverse reactions. It has also been responsible for fainting spells, dizziness and paralyzing neurologic disease called Guillain-Barre syndrome.

Some researchers from the Harvard School of Public Health decided to find out whether the use of Gardasil for men and boys to control cervical cancer in girls and women will be financially helpful.

“Even though it might be beneficial, whether or not the benefits are worth the investment is what we sought to evaluate,” said lead Harvard researcher Jane Kim.